Clinical Impact of Pharmaceutical Consultations in Patients Treated for Chronic Obstructive Pulmonary Disease at Home
NCT ID: NCT03704545
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
174 participants
INTERVENTIONAL
2019-01-18
2021-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State
NCT02103374
Effectiveness of Antibiotic Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease
NCT00495586
Analysis of Inhaled Corticoid Prescriptions in General Medicine
NCT03179826
A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
NCT01033487
An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease
NCT02366637
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
No interventions assigned to this group
Experimental group from the hospital
Pharmaceutical consultation at the hospital
During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
Experimental group from the city
Pharmaceutical consultation at the pharmacy
During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
Follow-up pharmaceutical consultation at the pharmacy
During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pharmaceutical consultation at the hospital
During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
Pharmaceutical consultation at the pharmacy
During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
Follow-up pharmaceutical consultation at the pharmacy
During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient is affiliated to a health insurance programme
* The patient is at least 18 years old (≥).
* The patient is admitted to complete hospitalization (for patients in the "Hospital and Control" groups).
* The patient is diagnosed with stage 2 to 4 Chronic Obstructive Pulmonary Disease. The diagnosis as well as the stage of the disease are validated by a pulmonologist at the facility.
* The patient has one or more inhaler devices to treat Chronic Obstructive Pulmonary Disease.
* The patient returns to his / her home when discharged from hospital (for patients in the "Hospital and Control" groups).
* The patient is available for a follow-up of 12 months.
Exclusion Criteria
* The subject is in an exclusion period determined by a previous study.
* The patient is under safeguard of justice.
* The subject refuses to sign the consent.
* It is not possible to give the patient (or his/her trusted-person) informed information.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nimes University Hospital
Nîmes, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hachemi D, Leguelinel-Blache G, Bouvet S, Roux-Marson C, Plouvier N, Kinowski JM, Castelli C, Dubois F. Clinical impact of pharmaceutical consultations in patients treated for chronic obstructive pulmonary disease: Study protocol for a randomized controlled trial (BPCObs study). Contemp Clin Trials Commun. 2023 Dec 20;37:101249. doi: 10.1016/j.conctc.2023.101249. eCollection 2024 Feb.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-A01699-46
Identifier Type: OTHER
Identifier Source: secondary_id
NIMAO/2017-03/JMK-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.